Exploring Cancer Patients' and Caregivers' Perspectives and Knowledge Regarding Biomarker Testing in Canada.

IF 3.4 4区 医学 Q2 ONCOLOGY
Patil Mksyartinian, Selina Xu, Chrissa Barroma, Sandra Peláez, Barry D Stein
{"title":"Exploring Cancer Patients' and Caregivers' Perspectives and Knowledge Regarding Biomarker Testing in Canada.","authors":"Patil Mksyartinian, Selina Xu, Chrissa Barroma, Sandra Peláez, Barry D Stein","doi":"10.3390/curroncol32060292","DOIUrl":null,"url":null,"abstract":"<p><p>While biomarker testing can provide various benefits for cancer patient outcomes, numerous challenges persist that cause inequities in access across Canada. An online survey consisting of 51 questions was disseminated to evaluate biomarker testing and precision medicine knowledge and experiences from Canadian patients and caregivers. Responses were recorded between June 2023 and January 2024 and assessed various aspects of the biomarker testing experience including the expectations and challenges of patients. Quantitative and qualitative analyses were conducted using Microsoft Excel and R for descriptive and correlative data analysis, respectively. Among the 74 responses, patients reported an overall moderate experience with positive outcomes for those who underwent biomarker testing, including changes to treatment plans and the shrinking of tumours. The main challenges identified included knowledge gaps, a lack of testing availability, turnaround time for results, and financial constraints, all of which contribute to the disparities in biomarker testing access. Qualitative analysis of responses further emphasized a strong patient desire for patient-centred care and collaborative decision-making for biomarker testing options and treatment planning. Addressing these challenges through increased education, policy advocacy, and advancing infrastructure can help to reduce interprovincial inequities in biomarker testing and contribute to improving cancer patient outcomes.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191459/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/curroncol32060292","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

While biomarker testing can provide various benefits for cancer patient outcomes, numerous challenges persist that cause inequities in access across Canada. An online survey consisting of 51 questions was disseminated to evaluate biomarker testing and precision medicine knowledge and experiences from Canadian patients and caregivers. Responses were recorded between June 2023 and January 2024 and assessed various aspects of the biomarker testing experience including the expectations and challenges of patients. Quantitative and qualitative analyses were conducted using Microsoft Excel and R for descriptive and correlative data analysis, respectively. Among the 74 responses, patients reported an overall moderate experience with positive outcomes for those who underwent biomarker testing, including changes to treatment plans and the shrinking of tumours. The main challenges identified included knowledge gaps, a lack of testing availability, turnaround time for results, and financial constraints, all of which contribute to the disparities in biomarker testing access. Qualitative analysis of responses further emphasized a strong patient desire for patient-centred care and collaborative decision-making for biomarker testing options and treatment planning. Addressing these challenges through increased education, policy advocacy, and advancing infrastructure can help to reduce interprovincial inequities in biomarker testing and contribute to improving cancer patient outcomes.

探讨加拿大癌症患者和护理人员对生物标志物检测的看法和知识。
虽然生物标志物检测可以为癌症患者的预后提供各种好处,但仍然存在许多挑战,导致加拿大各地的不公平准入。一项由51个问题组成的在线调查被分发,以评估加拿大患者和护理人员的生物标志物检测和精准医学知识和经验。在2023年6月至2024年1月期间记录反应,并评估生物标志物测试经验的各个方面,包括患者的期望和挑战。定量分析和定性分析分别使用Microsoft Excel和R进行描述性和相关数据分析。在74例反应中,接受生物标志物测试的患者报告了总体适度的积极结果,包括治疗计划的改变和肿瘤的缩小。确定的主要挑战包括知识差距、缺乏检测可用性、结果周转时间和资金限制,所有这些都导致了生物标志物检测获取的差异。对反应的定性分析进一步强调了患者对以患者为中心的护理和生物标志物检测选择和治疗计划的协作决策的强烈愿望。通过加强教育、政策宣传和推进基础设施来解决这些挑战,有助于减少生物标志物检测的省际不平等,并有助于改善癌症患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current oncology
Current oncology ONCOLOGY-
CiteScore
3.30
自引率
7.70%
发文量
664
审稿时长
1 months
期刊介绍: Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease. We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信